Amgen Starts New Technology Innovation Hub In City

Amgen, the largest biotechnology company in the United States, today inaugurated a new technology and innovation site in Hyderabad, marking an expansion of its operations in India.

The company has committed to investing approximately Rs 1,600 crore into the facility by the end of 2025.

The inauguration ceremony took place at Amgen's campus near HITEC City, with Telangana Chief Minister Revanth Reddy and IT and Industries Minister D Sridhar Babu presiding over the event. Amgen's Chairman and CEO Robert A Bradway, Executive Vice President and CTO David M Reese, US Consul General Jennifer Larson, Amgen India representative Som Chattopadhyay and Amgen India Managing Director Naveen Gullapalli were also in attendance.

Reddy expressed pride in welcoming one of the world's largest biotech firms to the city. He spoke of the significance of Amgen's expansion, and said that it reinforced Hyderabad's status as a global leader in innovation and technology. He also claimed that the government was committed to fostering a world-class life sciences ecosystem in Telangana.

CTO Reese spoke of the strategic importance of the new site, and said that the convergence of biotechnology and technology enabled the company to operate with greater speed, confidence and efficiency. He said that India's world-class talent in technology and life sciences was a key factor in selecting Hyderabad for this expansion.

Amgen currently employs 300 professionals in Hyderabad. With this new investment the company plans to double its workforce by the end of the year, and, over the next three to four years, to expand its Hyderabad team to 2,000 employees, positioning the city as a pivotal global hub for its operations. The facility is designed to accommodate up to 3,000 employees, and reflects the company's long-term growth plans in the region.

The Hyderabad site will focus on leveraging artificial intelligence and data science to enhance Amgen's digital capabilities, accelerating the development of new medicines. This initiative aligns with India's reputation as the "pharmacy of the world", and exemplifies the growing technological collaboration between the United States and India.